What Is Tesamorelin?
A partir de $53.55 · COAs de lote publicados para 1 de 2 tamanhos · Água BAC grátis + frete grátis nos EUA · Despacho no mesmo dia antes das 14h ET · APENAS PARA USO EM PESQUISA
Comprar peptídeo Tesamorelin - todos os tamanhosResposta Rapida
Tesamorelin (TH9507) e um(a) sintetico(a) 44-aminoacido analog of endogenous GHRH with a peso molecular of 5135.9 Da. It foi desenvolvido(a) por Theratechnologies Inc. to overcome the inherent instability of native GHRH, que has a meia-vida of apenas 3–8 minutes due to rapido(a) cleavage by DPP-4. [...
Tesamorelin — Quick Facts
| Molecular formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
|---|---|
| Molecular weight | 5135.9 Da g/mol |
| InChI key | VQFDKKWXORFBDI-VAVVJCQZSA-N |
| PubChem CID | 16137828 |
| Storage | Liofilizado: 2–8°C refrigerado, protegido da luz. Não congele. |
| Cited references | 24 |
Chemical identity from PubChem CID 16137828. For research use only.
Tesamorelin (TH9507) e um(a) sintetico(a) 44-aminoacido analog of endogenous GHRH with a peso molecular of 5135.9 Da. It foi desenvolvido(a) por Theratechnologies Inc. to overcome the inherent instability of native GHRH, que has a meia-vida of apenas 3–8 minutes due to rapido(a) cleavage by DPP-4. [1] [2]
Key Structural Feature: A trans-3-hexenoic acid group is anchored para o(a) N-terminal tyrosine (Tyr1), rendering o peptideo resistant to DPP-4 degradacao and extending the meia-vida to aproximadamente 26–38 minutes. C-terminal is amidated (-NH₂). [3]
Regulatory Status:
- FDA: Tesamorelin is the active ingredient of an FDA-approved pharmaceutical (Egrifta); that approval does not apply to this research-grade material. [4]
- EMA: Application withdrawn; not marketed no(a) EU. [6]
- WADA: Prohibited (S2 — Peptide Hormones, Growth Factors). [5]
Developer: Theratechnologies Inc. (Montreal, Canada) — originally designated TH9507.
Pharmacokinetic Highlights:
- Half-Life: ~26–38 min
- Pulsatility: Preserves natural pulsatile GH secretion (diferentemente de rhGH)
“Aviso sobre Estudos In Vitro / Pré-clínicos: Os achados de pesquisa descritos acima foram observados em estudos laboratoriais (in vitro) e/ou em modelos animais.”
Referencias
- Falutz J, Allas S, Kotler D, et al. AIDS, 19(12), 1279-87, 2005.
- Ferdinandi ES, Brazeau P, High K, et al. Basic Clin Pharmacol Toxicol, 100(1), 49-58, 2007.
- Falutz J, Allas S, Blot K, et al. N Engl J Med, 357(23), 2359-70, 2007.
- Falutz J, Mamputu JC, Potvin D, et al. J Clin Endocrinol Metab, 95(9), 4291-304, 2010.
- Wang Y, Tomlinson B. Expert Opin Investig Drugs, 18(3), 303-10, 2009.
- Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev compound Discov, 10(2), 95-6, 2011.
- Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. J Clin Endocrinol Metab, 96(1), 150-8, 2011.
- Dhillon S. Drugs, 71(8), 1071-91, 2011.
- Spooner LM, Olin JL. Ann Pharmacother, 46(2), 240-7, 2012.
- Stanley TL, Falutz J, Marsolais C, et al. Clin Infect Dis, 54(11), 1642-51, 2012.
- Stanley TL, Fourman LT, Feldpausch MN, et al. Lancet HIV, 6(12), e821-e830, 2019.
- Adrian S, Scherzinger A, Sanyal A, et al. J Frailty Aging, 8(3), 154-159, 2019.
- Baker LD, Barsness SM, Borson S, et al. Arch Neurol, 69(11), 1420-9, 2012.
- Lopez J, Quan A, Budihardjo J, et al. Growth Hormone Improves Nerve Regeneration, Muscle Re-innervation, and Functional Outcomes After Chronic Denervation Injury. Sci Rep, 9(1), 3117, 2019.
- Grinspoon SK, Fourman L, Stanley T, et al. Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores: Subanalysis. Open Forum Infect Dis, 12(Suppl 1), 2025.
- Clemmons DR, Miller S, Mamputu JC. PLoS One, 12(6), e0179538, 2017.
- Makimura H, Feldpausch MN, Rope AM, et al. J Clin Endocrinol Metab, 97(12), 4769-79, 2012.
- Fourman LT, Czerwonka N, Feldpausch MN, et al. AIDS, 31(16), 2253-9, 2017.
- Mangili A, Falutz J, Mamputu JC, et al. PLoS One, 10(10), e0140358, 2015.
- Lake JE, La K, Erlandson KM, et al. AIDS, 35(9), 1395-1402, 2021.
- Makimura H, Murphy CA, Feldpausch MN, Grinspoon SK. J Clin Endocrinol Metab, 99(1), 338-343, 2014.
- Stanley TL, Feldpausch MN, Oh J, et al. JAMA, 312(4), 380-9, 2014.
- Ellis RJ, Vaida F, Hu K, et al. J Infect Dis, 231(5), 1230-1238, 2025.
- Falutz J, Potvin D, Mamputu JC, et al. J Acquir Immune Defic Syndr, 53(3), 311-22, 2010.
Perguntas de Pesquisa Relacionadas
Related research
Browse all research guides in the Peptide Research Library →Deseja a revisao completa da pesquisa?
Comprar peptídeo Tesamorelin - todos os tamanhos→APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.
